Lung Cancer: New Plasma Biomarker for Non-Small Cell Cancer Interview with:
Jie He, PhD, MD
Director, Laboratory of Thoracic Surgery
President, Cancer Institute & Hospital, Chinese Academy of Medical Sciences
Chaoyang District, Beijing, 100021 What are the main findings of the study?

Dr. Jie He:  The main findings of the study is that we have identified IDH1 as an effective plasma biomarker for the diagnosis of NSCLCs, particularly with high sensitivity and specificity in the diagnosis of lung adenocarcinoma. Were any of the findings unexpected?

Dr. Jie He:  Yes, we feel a little surprised to see the results can be validated so good. So we are planning to conduct multi-center screenings to further validate the results. What should clinicians and patients take away from your report?

Dr. Jie He:  We have identified IDH1 as a new diagnositc marker for lung cancer, with a good proteintial to be used for noninvasive early diagnosis of lung cancer. What recommendations do you have for future research as a result of this study?

Dr. Jie He:  We are planning to conduct an independent cohort of patients for further validation. And it is necessary to determine whether plasma IDH1 can be used as a specific biomarker for NSCLCs against other cancers. Moreover, it is also necessary to study the molecular mechanism and clinical implications of IDH1 up regulation.


Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non–Small Cell Lung Cancer

Nan Sun, Zhaoli Chen, Fengwei Tan, Baihua Zhang, Ran Yao, Chengcheng Zhou, Jiagen Li, Yibo Gao, Ziyuan Liu, Xiaogang Tan, Fang Zhou, Max Y.f He, Kang Shao, Ning Li, Bin Qiu, Jian Sun, Yue Yu, Suya Wang, Yuda Zhao, Xuejiao Shi, and Jie He.  Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non–Small Cell Lung Cancer. Clinical Cancer Research, September 2013 DOI: 10.1158/1078-0432.CCR-13-004


Last Updated on September 19, 2013 by Marie Benz MD FAAD